Other · Acts on HER2 (ERBB2) · developed by Vir Biotechnology
VIR-5818 is an agent administered by intravenous infusion, studied in locally advanced or metastatic HER2-expressing cancers.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05356741 | Phase 1/2 | Locally Advanced or Metastatic HER2-Expressing Cancers | Recruiting | VIR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Locally Advanced or Metastatic HER2-Expressing Cancers
Updated Nov 1, 2026. Something wrong or missing? Report it on the VIR page.
See VIR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
VIR catalysts and pipeline →